m+Medelevator.RU
← Поиск публикаций
EMBO reports · 2026

Condensate-driven triglyceride reduction links α-synuclein to mitochondrial dysfunction.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Zhang Tao, Herron-Bedoya Alejandro, Eugenia Goya María, van der Weerd Jorien C, Tsagkari Dikaia, Couzijn Suzanne, Güngördü Lale, Ainslie Anna P, Seinstra Renée I, Heiner Fokkema M Rebecca, Chang Ming, Tavernarakis Nektarios, Kuipers Folkert, Nollen Ellen A A

Аннотация

α-Synuclein (αSyn) inclusions characterize multiple age-related neurodegenerative diseases, including Parkinson's disease (PD). While interactions between αSyn and lipids are known to contribute to αSyn pathobiology, the precise cellular mechanisms linking lipids to αSyn toxicity have yet to be elucidated. Through lipidomic profiling of Caenorhabditis elegans, we find that αSyn progressively alters lipid metabolism in aging worms. αSyn reduces the overall content of triacylglycerols (TAG) and disrupts the structure of lipid droplets (LD) and mitochondria. These pathological changes depend on αSyn's properties to bind lipid and to condensate into inclusions. Apart from lowering TAG levels, αSyn proportionally increases long-chain unsaturated fatty acids (LCUFAs). Consequently, genetic inhibition of LCUFA biosynthesis alleviates αSyn-induced loss of C. elegans motility. Supplementing Medium-Chain Triglyceride (MCT) on the other hand also improves αSyn-associated toxicity phenotypes. These results link αSyn lipid binding and condensation to impaired TAG metabolism, which drives cellular toxicity. Combined with observed lower plasma TAGs in Parkinson cohorts, our findings reveal contributions of TAG remodelling to αSyn toxicity and point at MCT-supplementation as a mechanism-based therapeutic opportunity in age-related synucleinopathies.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты